In adults living with HIV, the 21-valent pneumococcal conjugate vaccine (PCV) V116 was well tolerated and effective against all 21 target serotypes. The immune responses were comparable to those ...
The inequalities gap in uptake rates of pneumococcal vaccine for vulnerable groups is widening and simplifying the vaccine schedule has not reduced this, researchers from the University of Liverpool ...
Newspoint on MSN
Pneumonia vaccine: Are you over 50 and experiencing frequent coughs and colds? Know when you need the pneumonia vaccine.
Pneumonia Risk Factors: Doctors recommend getting the pneumonia vaccine, also known as the pneumococcal vaccine. This vaccine ...
—Among adults, coverage and preventable burdens were lowest for pneumococcal conjugate vaccine (PCV) 15 and highest for PCV31, with PCV21 preventing notable burdens of both acute respiratory ...
1 dose ≥8wks after last PCV dose 12 No additional vaccine 6 PCV15 or PCV20 1 dose ≥8wks after last pneumococcal vaccine 8 If PCV15 used, also give PPSV23 ≥8wks after the last PCV dose if not ...
Credit: Getty Images. V116 is an investigational 21-valent pneumococcal conjugate vaccine. Merck’s investigational 21-valent pneumococcal conjugate vaccine, V116, elicited positive immune responses in ...
-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in Adults Following Independent Review of Phase 1 Safety and Tolerability Data; Topline Safety, Tolerability ...
After pneumococcal disease and colonization have been controlled through vaccination campaigns, a reduced pneumococcal conjugate vaccine (PCV) schedule may be sufficient to sustain that control at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results